PFE
Pfizer Inc.
28.32
5400 x 28.29
16100 x 28.26
bid
ask
-
0.23
0.81%
10750 @ 04:02 PM
28.30 -0.02 (0.07%)
Ytd 13.73%
1y 14.66%
28.22
day range
28.75
21.59
52 week range
28.55
Open 28.50 Prev Close 28.55 Low 28.22 High 28.75 Mkt Cap 161.09B
Vol 21.41M Avg Vol 45.93M EPS 1.36 P/E 20.82 Forward P/E 10.04
Beta 0.41 Short Ratio 3.49 Inst. Own 67.68% Dividend 1.72 Div Yield 6.02
Ex Div Date 01-23 Earning 05-05 50-d Avg 27.00 200-d Avg 25.46 1yr Est 28.58
Earning
Date For Estimate Reported Surprise surprise %
2026-05-05 2026-03 0.77 N/A N/A N/A
2026-02-03 2025-12 0.57 0.66 0.09 15.79%
2025-11-04 2025-09 0.66 0.87 0.21 31.82%
2025-08-05 2025-06 0.58 0.78 0.2 34.48%
2025-04-29 2025-03 0.64 0.92 0.28 43.75%
2025-02-04 2024-12 0.48 0.63 0.15 31.25%
Upgrade / Downgrade
Date Firm Action From To
2026-03-24 Guggenheim Upgrade Buy Buy
2026-03-17 HSBC Upgrade Buy Buy
2026-03-02 Argus Research Upgrade Hold Buy
2026-02-25 RBC Capital Upgrade Underperform
2026-02-20 Barclays Upgrade Underweight
2026-02-09 Freedom Broker Upgrade Buy Buy
Profile
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It also provides inflammation and immunology products, such as Xeljanz, Enbrel, Cibinqo, Litfulo, Eucrisa, and Velsipity; rare disease products for therapeutic areas comprising amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel family, Genotropin, BeneFIX, Xyntha, Somavert, Ngenla, and Hympavzi brands; and anti-infective and immunoglobulin medicines under the Zavicefta, Octagam, and Panzyga brands. In addition, the company offers oncology products comprising ADCs, small molecules, bispecific, and other immunotherapies for the treatment of cancers, including breast cancer, genitourinary cancer, and hematologic malignancies, as well as melanoma, gastrointestinal, gynecological, and lung cancer under the Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak, and Talzenna brands. Further, it provides biosimilars under the Inflectra brand; oncology biosimilars comprising Retacrit, Ruxience, Zirabev, Trazimera and Nivestym, and other biosimilars; and sterile injectables, such as Sulperazon, Atgam, Fragmin, Solu Medrol, Solu Cortef, and Bicillin. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE, as well as a strategic collaboration with Boltz, PBC to develop and deploy biomolecular AI foundation models. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.
Insider Holder
Date Name Relation Quantity Description
2025-02-12 BLAYLOCK RONALD E Director 32.46K Purchase
2026-02-24 BOSHOFF CHRISTOFFEL Officer 162.09K Stock Award(Grant)
2026-02-24 BOURLA ALBERT Chief Executive Officer 394.67K Conversion of Exercise of derivative security
2026-03-02 DAMICO JENNIFER B. Officer 32.93K Stock Award(Grant)
2026-02-24 FONSECA LIDIA PH.D. Officer 46.46K Conversion of Exercise of derivative security
2024-10-29 GOTTLIEB SCOTT Director 10.00K Purchase
Institution Ownership
Report Date Organization Position Value Percentage
2025-12-30 Vanguard Group Inc 541.35M 15.33B 9.52%
2025-12-30 Blackrock Inc. 493.06M 13.96B 8.67%
2025-12-30 State Street Corporation 300.45M 8.51B 5.28%
2025-12-30 Geode Capital Management, LLC 130.19M 3.69B 2.29%
2025-12-30 Morgan Stanley 89.11M 2.52B 1.57%
2025-12-30 NORGES BANK 73.53M 2.08B 1.29%
Fund Ownership
Report Date Organization Position Value Percentage
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund 178.79M 5.06B 3.14%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard 500 Index Fund 143.37M 4.06B 2.52%
2026-01-30 iShares Trust-iShares Core S&P 500 ETF 73.17M 2.07B 1.29%
2026-02-27 Fidelity Concord Street Trust-Fidelity 500 Index Fund 72.36M 2.05B 1.27%
2026-01-30 SPDR S&P 500 ETF TRUST-State Street SPDR S&P 500 ETF Trust 68.28M 1.93B 1.20%
2025-12-30 VANGUARD INDEX FUNDS-Vanguard Value Index Fund 52.32M 1.48B 0.92%
Dividend
Dividend Date
0.43 2026-01-23
0.43 2025-11-07
0.43 2025-07-25
0.43 2025-05-09
0.43 2025-01-24
0.42 2024-11-08
Split
Split Date
1054 : 1000 2020-11-17
3 : 1 1999-07-01
2 : 1 1997-07-01
2 : 1 1995-07-03
2 : 1 1991-04-01
2 : 1 1983-07-01